Summary
Scientists, medical professionals and the public know that by the time new flu vaccines are produced for use that the specific outbreak is far into the past and the vaccine is no longer in need and is destroyed. Novartis and other vaccine production companies need to dedicate more effort in evaluation of existing and new vaccines.
Analysis
Subparticulate vaccines with combined H and N autogeny specific to past epidemics along with various sequenced antigen subunits could be developed for future immediate use. This may sound simplistic but, at least, this approach has a chance for success in providing needed immunity and for evaluation of vaccine use.
This author consults with leading institutions through GLG
Analyses are solely the work of the authors and have not been edited or endorsed by GLG.
